Experienced in Teratoma of the Mediastinum

Christine Spitzweg

Munich, BY, DE 
Experienced in Teratoma of the Mediastinum
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Christine Spitzweg practices in Munich, Germany. Ms. Spitzweg is rated as an Experienced expert by MediFind in the treatment of Teratoma of the Mediastinum. Her top areas of expertise are Medullary Thyroid Carcinoma, Thyroid Cancer, Anaplastic Thyroid Cancer, Neuroendocrine Tumor, and Thyroidectomy.

Her clinical research consists of co-authoring 135 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Teratoma of the Mediastinum.

Gender
Female

Locations

Munich, BY, Germany
Other Locations
Martinsried, BY 82152, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3

135 Total Publications

Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Journal: Targeted oncology
Published: August 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Spitzweg's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile